Abiraterone Acetate Tablet
Product Images NDC 60687-790

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Abiraterone Acetate (NDC 60687-790). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by American Health Packaging, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

250 mg Abiraterone Acetate Tablet Blister (250 mg Abiraterone Acetate Tablet Blister)

250 mg Abiraterone Acetate Tablet Blister (250 mg Abiraterone Acetate Tablet Blister)
FDA Label Image

250 mg Abiraterone Acetate Tablets Carton (250 mg Abiraterone Acetate Tablets Carton)

250 mg Abiraterone Acetate Tablets Carton (250 mg Abiraterone Acetate Tablets Carton)
This is information related to NDC 60667-790-21, which includes abiraterone acetate tablets in 30-tablet packaging. The tablets contain 250mg of Abiraterone Acetate, USP. A warning is issued to women who are pregnant or may become pregnant to avoid handling the tablets. The recommended dosage should be followed and the tablets should be swallowed whole without crushing or chewing. Storage instructions include keeping the product between 20°C to 25°C (68°F to 77°F). The product is distributed by American Health Packaging.*
FDA Label Image

Ahp79021

Ahp79021
FDA Label Image

Figure 1: Kaplan-meier Overall Survival Curves In Cou-aa-301 (intent-to-treat Analysis) (Figure 1)

Figure 1: Kaplan-meier Overall Survival Curves In Cou-aa-301 (intent-to-treat Analysis) (Figure 1)
This text appears to be a table showing "Abiraterone Acetate" and "Placebo" options with corresponding numerical values indicating time to death in months. The values seem to be different over time intervals from 0 to 21 months for both options.*
FDA Label Image

Figure 2: Kaplan Meier Overall Survival Curves In Cou-aa-302 (Figure 2)

Figure 2: Kaplan Meier Overall Survival Curves In Cou-aa-302 (Figure 2)
FDA Label Image

Figure 3: Kaplan Meier Curves Of Radiographic Progression-free Survival In Cou-aa-302 (intent-to-treat Analysis) (Figure 3)

Figure 3: Kaplan Meier Curves Of Radiographic Progression-free Survival In Cou-aa-302 (intent-to-treat Analysis) (Figure 3)
FDA Label Image

Figure 4: Kaplan-meier Plot Of Overall Survival; Intent-to-treat Population In Latitude Updated Analysis (Figure 4)

Figure 4: Kaplan-meier Plot Of Overall Survival; Intent-to-treat Population In Latitude Updated Analysis (Figure 4)
This text appears to be a data table showing the survival of subjects without death in two groups: one group treated with Abiraterone acetate and the other with Placebo. The number of subjects at risk in each group is provided at various time points. The data seem to indicate a comparison of survival rates between the two groups over time.*
FDA Label Image

Structural Formula (Structural Formula)

Structural Formula (Structural Formula)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.